In silico selection approach to develop DNA aptamers for a stem-like cell subpopulation of non-small lung cancer adenocarcinoma cell line A549
Article Category: Research Article
Published Online: Mar 25, 2018
Page range: 152 - 159
Received: Nov 24, 2017
Accepted: Feb 26, 2018
DOI: https://doi.org/10.2478/raon-2018-0014
© 2018 Mateja Vidic, Tina Smuc, Nika Janez, Michael Blank, Tomaz Accetto, Jan Mavri, Isis C. Nascimento, Arthur A. Nery, Henning Ulrich, Tamara T. Lah, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
Detection of circulating lung cancer cells with cancer-stem like characteristics would represent an improved tool for disease prognosis. However, current antibodies based methods have some disadvantages and therefore cell SELEX (Systematic Evolution of Ligands by Exponential Enrichment) was used to develop DNA aptamers, recognizing cell surface markers of non-small lung carcinoma (NSLC) cells.
Materials and methods
The human adenocarcinoma cell line A549 was used for selection in seven cell SELEX cycles. We used human blood leukocytes for negative selection, and lung stem cell protein marker CD90 antibody binding A549 cells for positive selection.
Results
The obtained oligonucleotide sequences after the seventh SELEX cycle were subjected to
Conclusions
The novel aptamer A155_18 has strong binding affinity for A549 lung carcinoma cell line subpopulation that is expressing stem cell marker CD90, indicating a possible stemness, characteristic for the A459 line, or a subpopulation present within this cell line. This aptamer can be applied as diagnostic tool, identifying NSLC circulating cells.